Human testis harbors HIV-1 in resident immune cellsNovember 27, 2006Rennes, France - Researchers have demonstrated HIV replication within resident immune cells of the testis, providing an explanation for the persistence of virus in semen even after effective highly active antiretroviral therapy. The related report by Roulet et al., "Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro," appears in the December issue of The American Journal of Pathology. According to the most recent World Health Organization data, 39.5 million people are infected with HIV. Semen remains the main means of spreading the virus, even though highly active antiretroviral therapy (HAART) can successfully suppress virus in the blood. The presence of HIV in the semen despite successful HAART has intrigued scientists. Researchers led by Dr. Nathalie Dejucq-Rainsford examined testis tissue for the presence of HIV receptors. They found that all of the necessary cellular receptors (CD4, CXCR4, CCR5, and DC-SIGN) were present on cells located within the testis, specifically testicular macrophages. The point was demonstrated further by using explanted organ cultures in which human testis tissue was grown in culture. This testis culture, which retained the same tissue architecture as in vivo tissue and continued to secrete testosterone, was able to support infection by HIV-1. Virus produced from the testis culture was fully active as collected virus was able to infect permissive cells in culture. The finding that HIV-1 can replicate within testicular macrophages is significant because the testis represents a pharmacological sanctuary-many anti-retroviral drugs have difficulty penetrating this organ and may be present at sub-therapeutic levels. Thus, although HAART may achieve undetectable virus levels in the blood, virus replication in the testis may permit continued spread of the virus. Finally, with HIV infection continuing to rise, the development of anti-retroviral therapy that effectively targets all sources of HIV, including the testis, is gravely needed. The use of this testis culture system may allow assessment of new anti-retroviral drugs that target HIV in the testis. American Journal of Pathology |
|||||||||||||||||||||
| Related HIV-1 Current Events and HIV-1 News Articles Hoping for a fluorescent basket case Although recent advances have raised hopes that a protective vaccine can be developed, acquired immunodeficiency syndrome (AIDS) remains a major public health problem. Maternal HIV-1 treatment protects against transmission to newborns Mothers receiving highly active antiretroviral therapy (HAART) to treat HIV-1 infection are less likely than untreated mothers to transmit the virus to their newborns through breastfeeding. Scientists join forces to explain HIV spread in Central and East Africa Scientists studying biology and geography may seem worlds apart, but together they have answered a question that has defied explanation about the spread of the HIV-1 epidemic in Africa. Researchers induce HIV-neutralizing antibodies that recognize HIV-1 envelope protein, lipids For the first time, researchers have experimentally induced antibodies that neutralize HIV-1 and simultaneously recognize both HIV-1 envelope protein and lipids. Link uncovered between viral RNA and human immune response In its fight against an intruding virus, an enzyme in our immune system may sense certain types of viral RNA pairs, according to scientists. In vitro antibody production enables HIV infection detection in window period -- key to safer blood Researchers in Israel and Kenya have shown that the contribution of variable degrees of immune suppression, either due to existing chronic infections such as parasitemias and/or nutrition, in different populations may influence and prolong the serological-diagnostic window period of HIV. AIDS discovered in wild chimpanzees Although the AIDS virus (HIV-1) entered the human population through chimpanzees, scientists have long believed that chimpanzees don't develop AIDS. Penn-Wistar team gains insight into HIV vaccine failure A team of researchers from The Wistar Institute and the University of Pennsylvania reports new evidence refuting a popular hypothesis about the highly publicized failure in 2007 of the Merck STEP HIV vaccine study that cast doubt on the feasibility of HIV-1 vaccines. Genetic Variation Associated With Survival Advantage in African Americans With HIV From the start of the HIV epidemic, it appeared that some of the people who were infected with the virus were able to ward off the fatal effects of the disease longer than others. Study offers insights into failed HIV-1 vaccine trial Following the disbandment of the STEP trial to test the efficacy of the Merck HIV-1 vaccine candidate in 2007, the leading explanation for why the vaccine was ineffective - and may have even increased susceptibility to acquiring the virus - centered on the hypothesis that high levels of baseline Ad5-specific neutralizing antibodies may have increased HIV-1 acquisition among the study subjects who received the vaccine by increasing Ad5-specific CD4+ T-cells that were susceptible to HIV-1 infection. More HIV-1 Current Events and HIV-1 News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||